Harvard Bioscience Inc. To Present At The Conference On May 9 In New York
Harvard Bioscience, Inc. , a global developer, manufacturer, and marketer of a broad range of solutions to advance life science, will present at the Sidoti Ninth Semiannual Micro-Cap Conference in New York City on May 9, 2014.
Harvard Apparatus Regenerative Technology; A Strategic Plan To Profitability
HART's solution to tracheal cancer or trauma can be evaluated for efficacy within one year, the expected survival time remaining for patients with no other solution but surgical implantation.
SeeThruEquity Issues Update on Harvard Bioscience Inc.
New York, NY / ACCESSWIRE / April 17, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update note on Harvard Bioscience Inc. regarding financial and operational results for Q4 2013 and FY 2013.
Regenerated Esophagus Successfully Transplanted Into Rat
A research team led by Paolo Macchiarini , MD, PhD at Karolinska Institutet in Sweden has successfully transplanted a regenerated esophagus into a rat using a bioreactor developed by Harvard Apparatus Regenerative Technology , a spin-off of Harvard Bioscience.
Harvard Bioscience Director David Green Sells 63,501 Shares
Harvard Bioscience Director David Green unloaded 63,501 shares of Harvard Bioscience stock on the open market in a transaction that occurred on Thursday, April 3rd.
The Motley Fool
I'm Selling Harvard Biosciences
Not bad. But the outlook for the parent company is not as rosy as I had expected, and my expectations were not that high to begin with.